Impact of polymorphisms in DNA repair genes XPD, hOGG1 and XRCC4 on colorectal cancer risk in a Chinese Han Population

Dexi Jin¹, Min Zhang² and Hongjun Hua³

¹Department of Gastrointestinal Surgery, the Affiliated Wenling Hospital of Wenzhou Medical University, the First People’s Hospital of Wenling, Zhejiang, China; ²Department of Gastroenterology, Shanxian Dongda Hospital, Shandong, China; ³Department of Gastroenterology, Jinhua Central Hospital, Jinhua Hospital of Zhejiang University, Zhejiang, China

Correspondence: HongJun Hua (18267052506@163.com)

Background: This research aimed to study the associations between XPD (G751A, rs13181), hOGG1 (C326G, rs1052133) and XRCC4 (G1394T, rs6869366) gene polymorphisms and the risk of colorectal cancer (CRC) in a Chinese Han population. Method: A total of 225 Chinese Han patients with CRC were selected as the study group, and 200 healthy subjects were recruited as the control group. The polymorphisms of XPD G751A, hOGG1 C326G and XRCC4 G1394T loci were detected by the RFLP-PCR technique in the peripheral blood of all subjects. Results: Compared with individuals carrying the XPD G allele (GA/AA), the A allele carriers (GA/AA) had a significantly increased risk of CRC (adjusted OR = 2.109, 95% CI = 1.352–3.287, P = 0.003). Similarly, the G allele (CG/GG) of hOGG1 C326G locus conferred increased susceptibility to CRC (adjusted OR = 2.654, 95% CI = 1.915–3.685, P < 0.001). In addition, the T allele carriers (GT/TT) of the XRCC4 G1394T locus have an increased risk of developing CRC (adjusted OR = 4.512, 95% CI = 2.785–7.402, P < 0.001). The risk of CRC was significantly increased in individuals with both the XPD locus A allele and the hOGG1 locus G allele (adjusted OR = 1.543, 95% CI = 1.302–2.542, P = 0.002). Furthermore, individuals with both the hOGG1 locus G allele and the XRCC4 locus T allele were predisposed to CRC development (adjusted OR = 3.854, 95% CI = 1.924–7.123, P < 0.001). The risks of CRC in XPD gene A allele carriers (GA/AA) (adjusted OR = 1.570, 95% CI = 1.201–1.976, P = 0.001), hOGG1 gene G allele carriers (CG/GG) (adjusted OR = 3.031, 95% CI = 2.184–4.225, P < 0.001) and XRCC4 gene T allele carriers (GT/TT) (adjusted OR = 2.793, 95% CI = 2.235–3.222, P < 0.001) were significantly higher in patients who smoked ≥16 packs/year. Conclusion: Our results suggest that XPD G751A, hOGG1 C326G and XRCC4 G1394T gene polymorphisms might play an important role in colorectal carcinogenesis and increase the risk of developing CRC in the Chinese Han population. The interaction between smoking and these gene polymorphisms would increase the risk of CRC.

Introduction

Colorectal cancer (CRC) is currently the third most common malignancy worldwide and ranks fourth in cancer-related mortalities [1]. Together with economic bloom, improvement in quality of life, changes in dietary patterns and environmental deterioration, the incidence of CRC is sharply increasing in developing countries including China [1]. According to the registration data collected from the National Central Registry of China, 3,763,000 new CRC cases (2,157,000 for male and 1,606,000 for female) and 1,910,000 cancer deaths (1,111,000 for male and 800,000 for female) were estimated from 2009 to 2011 [2]. The exact mechanisms underlying colorectal carcinogenesis remain unknown despite the epidemiological data indicating that numerous factors might contribute to the etiology of CRC, including high rates of red meat.
consumption, tobacco use, alcohol intake, lack of exercise and family history [3]. However, these conventional risk factors do not fully account for all cases, especially in young subjects, who often do not have any of these factors. In addition, family history of tumors significantly increased susceptibility to CRC, which showed that genetic factors might be related to CRC etiology, similar to the etiology of any other major malignancy [4,5].

A common type of genetic variation in the genome, known as single-nucleotide polymorphism (SNP), has been found to be associated with susceptibility to cancer [6]. Many of these polymorphisms are found in the genes that regulate potentially oncogenic pathways [6]. The DNA repair pathways play critical roles in maintaining genome integrity, and a diminished capacity to repair DNA lesions predisposes individuals to an increased susceptibility to cancer [7,8]. Individuals with CRC have been shown to have a lower DNA repair capacity [9,10]. We hypothesize that genetic polymorphisms in DNA repair genes may affect DNA repair capacity and increase the risk of CRC in a specified population. There are multiple DNA repair genes, each dealing with specific DNA damage [7]. Xeroderma pigmentosum group D (XPD), 8-oxoguanine DNA-glycosylase 1 (hOGG1) and X-ray repair cross-complementing protein 4 (XRCC4) are among the key DNA repair genes; XPD is thought to be involved in the nucleotide excision repair, hOGG1 is implicated in repairing oxidatively damaged DNA and DNA single-strand breaks, and XRCC4 primarily addresses DNA double-strand breaks, repaired by homologous and nonhomologous end-joining recombination (NHEJ) [11–13].

To obtain a comprehensive estimate of the putative influence of the genetic polymorphisms of these genes on CRC risk, XPD G751A, hOGG1 C326G and XRCC4 G1394T polymorphisms in CRC patients were detected in this case–control study in a sample of the Chinese population with the aim of providing a theoretical basis for the treatment and prognosis of the disease.

Materials and methods
Patient characteristics
This based case–control study was conducted from August 2014 until October 2017. A total of 225 consecutive CRC patients (140 males, 85 females; aged 53.1 ± 11.2 years) who underwent surgical resection at the Gastrointestinal Surgery, the Affiliated Wenling Hospital of Wenzhou Medical University were enrolled in the present study as the observation group, whereas 200 age- and sex-matched controls (118 males, 82 females; aged 49.7 ± 11.2 years) were individuals who received health screening at Tongde Hospital of Zhejiang. Subjects in the observation group were sporadic CRC patients without a family history of CRC. All individuals enrolled in the present study had no chronic diseases including diabetes mellitus, hypertension, cardiovascular and cerebrovascular disease, chronic kidney disease or other systemic diseases. All patients with CRC did not receive radiotherapy or chemotherapy before surgery. The data collected included sex, age, smoking and alcohol intake habits, tumor location, T stage and grade, lymph node status, distant metastases, and neoadjuvant chemotherapeutic treatment. Informed consent was obtained from all subjects. The study was approved by the Ethics Committee of the Affiliated Wenling Hospital of Wenzhou Medical University.

DNA extraction and gene polymorphism detection
Peripheral venous blood (5 ml) was obtained from all subjects in the morning, while they were in a fasting state. Genomic DNA was extracted using the DNeasy Kit (QIAamp DNA Blood Midi Kit, Qiagen, Cat#51104, Hilden, Germany) according to the manufacturers’ instructions. The extracted DNA was stored at −80°C for further use. The XPD G751A, hOGG1 C326G and XRCC4 G1394T polymorphisms were genotyped using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. The primers and restriction enzymes for determining XPD G751A, hOGG1 C326G and XRCC4 G1394T genotypes were shown in Table 1. The 25-μl PCR reaction system was used, containing 2.5 μl Taq polymerase buffer solution, 2 μl magnesium chloride (2 mM), 2 μl dNTP mix (0.2 mM), 1 μl forward primer (10 pmol), 1 μl reverse primer (10 pmol), 2 μl genomic DNA (100 ng/μl), 0.5 μl Taq polymerase enzyme and 14 μl distilled water. The PCR amplification conditions were as follows: denaturation at 94°C for 4 min, then 35 cycles of denaturation at 94°C for 30 s, annealing at 52°C for 30 s, and extension at 72°C for 1 min. The PCR reaction products were treated with the appropriate restriction enzymes in 37°C water overnight, and the digested products were separated by electrophoresis in 2% agarose gels. Finally, an ultraviolet gel imager was used to visualize the electrophoretic results and determine sample genotypes. The PCR product information for the XPD G751A, hOGG1 C326G and XRCC4 G1394T variants were shown in Figure 1.
Table 1 Amplification primers and PCR amplification product information

| Genotype   | Primer sequence (forward and reverse) | PCR product | Restriction | Restriction products |
|------------|--------------------------------------|-------------|-------------|----------------------|
| XPD G751A  | CCTCTCCCTTTTCTCTGTC                  | 734bp       | PstI        | GG:734bp; GA:734bp; 646bp, 88bp; AA:646bp, 88bp |
| hOGG1 C326G| CAGGTCAGGAGGGACATCT                  | 293bp       | Fnu4HI      | CC:293bp; CG:169bp,124bp; GG:124bp |
| XRCC4 G139T| CAGGTGAGGGGGACATCT                   | 300bp       | HincII      | GG:100bp; GT:200bp |

Figure 1. Detection of XPD, hOGG1 and XRCC4 polymorphisms through PCR/FFLP

(A) lane 1: XPD GG genotype; lane 2: XPD GA genotype; lane 3: XPD AA genotype. (B) lane 1: hOGG1 CC genotype; lane 2: hOGG1 CG genotype; lane 3: hOGG1 GG genotype. (C) lane 1: XRCC4 GG genotype; lane 2: XRCC4 GT genotype; lane 3: XRCC4 TT genotype.

Statistical analysis

Statistical analyses were conducted with the SPSS 18.0 software package (SPSS Inc, Chicago, IL). The heredity equilibrium was assessed by the Hardy–Weinberg test, and the differences in genotype frequencies of XPD G751A, hOGG1 C326G and XRCC4 G1394T between the CRC patient group and the control group were evaluated by the chi-square test. The linkage disequilibrium of gene polymorphisms was measured by D₀, and the r² value was calculated via the Haploview program (http://www.broad.mit.edu/mpg/haploview/). The correlations between polymorphism phenotype alleles and clinicopathological parameters, demographic variables and environmental factors were analyzed by the chi-square test or the Fisher exact test. The odds ratios (OR) with the 95% confidence interval (CI) were calculated to analyze the strength of the association of polymorphism phenotype alleles with CRC risk. Bonferroni adjustments were made for P-values for the results of any SNP by multiplying the number of SNPs tested for the gene. Receiver operating characteristic (ROC) curve analysis was performed to determine the optimal cut-off value to divide the smoking status between two groups. All P-values were two-sided, and *P<0.05 was considered to indicate statistical significance.

Results

Population characteristics

At baseline, no statistically significant differences between the study and control groups were noted regarding demographics (age and sex), BMI, smoking and alcohol status (Supplementary Table S1). The clinical diagnosis/staging of CRC was performed according to the Union for International Cancer Control (UICC) classification, and 74 patients with CRC received neoadjuvant chemotherapeutic treatment that lasted for 2 months. Among the CRC patients, 49.33% of lesions (111 cases) occurred in the colon, and 50.67% of lesions (114 cases) occurred in the rectum. There were 11 cases (4.89%) of T1 stage, 54 cases (24.00%) of T2 stage, 111 cases (49.33%) of T3 stage and 49 cases (21.78%) of T4 stage. A total of 77 cases (34.22%) had no lymphocyte metastases, denoted as N0, 36 cases (34.2%) were N1, 28 cases (12.44%) were N1a, 30 cases (13.33%) were N1b, 30 cases (13.33%) were N1 and 24 cases (10.67%) were N2. Regarding the tumor stages, 66 cases (29.33%), 102 cases (45.33%), 31 cases (13.78%) and 26 cases (11.56%) had stages I, II, III and IV disease, respectively. Forty-eight CRC patients (21.33%) had distant metastases, and the rest (177 cases, 78.67%) did not show signs of remote metastases.
Table 2 Distribution of XPD751, hOGG1, XRCC4 polymorphisms and CRC risk

| Gene and genotype | CRC group (n=225) | Control group (n=200) | HWE χ² | HWE P-value | Crude OR (95%CI) | P-value | Adjusted OR (95%CI) | P-value |
|-------------------|-------------------|-----------------------|--------|------------|-----------------|---------|-------------------|---------|
| XPD G751A         |                   |                       |        |            |                 |         |                   |         |
| GG                | 164 (72.89%)      | 167 (83.50%)          | 1.62   | 0.20       | 1               | –       | 1                 | –       |
| GA                | 56 (24.89%)       | 33 (16.50%)           |        |            | 1.728           | 0.025   | 1.705             | 0.034   |
|                    |                   |                       |        |            | (1.040–2.877)   |         | (1.028–2.698)     |         |
| AA                | 5 (2.22%)         | 0                     | –      | –          | –               | –       | –                 | –       |
| Allele            |                   |                       |        |            |                 |         |                   |         |
| G                 | 378 (84.00%)      | 367 (91.75%)          |        |            | 2.118           | 0.001   | 2.109             | 0.003   |
| A                 | 72 (16.00%)       | 33 (8.25%)            |        |            | (1.341–3.356)   |         | (1.352–3.287)     |         |
| hOGG1 C326G       |                   |                       |        |            |                 |         |                   |         |
| CC                | 88 (39.11%)       | 138 (69.00%)          | 0.01   | 0.91       | 1               | –       | 1                 | –       |
| CG                | 114 (50.67%)      | 56 (28.00%)           | 3.192  | <0.001     | 3.158           | <0.001 | (2.057–4.865)     | <0.001 |
| GG                | 23 (10.22%)       | 6 (3.00%)             | 6.01   | <0.001     | 6.024           | <0.001 | (2.231–17.351)    | <0.001 |
| Allele            |                   |                       |        |            |                 |         |                   |         |
| C                 | 290 (64.44%)      | 332 (83.00%)          | 2.694  | <0.001     | 2.654           | <0.001 | (1.915–3.685)     | <0.001 |
| G                 | 160 (35.56%)      | 68 (17.00%)           |        |            | (1.932–3.777)   |         |                   |         |
| XRCC4 G139T       |                   |                       |        |            |                 |         |                   |         |
| GG                | 137 (60.89%)      | 176 (88.00%)          | 0.81   | 0.37       | 1               | –       | 1                 | –       |
| GT                | 76 (33.78%)       | 24 (12.00%)           | 4.068  | <0.001     | 4.054           | <0.001 | (2.368–7.054)     | <0.001 |
| TT                | 12 (5.33%)        | 0 (0.00%)             | –      | –          | –               | –       | –                 | –       |
| Allele            |                   |                       |        |            |                 |         |                   |         |
| G                 | 350 (77.78%)      | 376 (84.00%)          | 4.476  | <0.001     | 4.512           | <0.001 | (2.785–7.402)     | <0.001 |
| T                 | 100 (22.22%)      | 24 (6.00%)            |        |            | (2.741–7.360)   |         |                   |         |

*OR* adjusted by age, sex, alcohol and smoking; CI, confidence interval; HWE, Hardy–Weinberg equilibrium.

XPD, hOGG1, XRCC4 gene polymorphisms and CRC risk

The genotypic frequencies of polymorphisms were ascertained in a balanced state in the Han Chinese population, based on the Hardy–Weinberg equilibrium (*P* > 0.05). Table 2 summarizes the associations of gene polymorphisms (XPD, hOGG1 and XRCC4) with CRC. For the XPD G751A polymorphism, our results revealed that individuals carrying the A allele (AG+AA) were associated with a significantly increased risk of CRC (OR = 2.118, 95%CI = 1.341–3.356, *P* = 0.001; adjusted OR = 2.109, 95%CI = 1.352–3.287, *P* = 0.003). Our results also suggested that the G allele carriers (CG+GG) of the hOGG1 C326G polymorphism were predisposed to CRC development, (OR = 1.71, 95%CI = 1.09–2.69, *P* = 0.019). Similarly, a significant association between the XRCC4 G1394T polymorphism and susceptibility to CRC was observed in this case–control study (OR = 4.476, 95%CI = 2.741–7.360, *P* < 0.001; adjusted OR = 4.512, 95%CI = 2.785–7.402, *P* < 0.001) (Table 2).

The joint effect of XPD, hOGG1 and XRCC4 gene polymorphisms on CRC risk

Gene loci of XPD G751A, hOGG1 C326G and XRCC4 G1394T were not interlinked (D², 0.005; r², 0.002). According to the frequencies of the relevant genotypes for XPD G751A, hOGG1 C326G and XRCC4 G1394T, a simultaneous occurrence of the XPD locus A allele, the XRCC4 locus T allele and the hOGG1 locus C allele was deemed risk-free. Given that all three polymorphisms, XPD G751A, hOGG1 C326G and XRCC4 G1394T, were not found in any individual, we examined the pairwise joint effect of variant alleles of XPD G751A, hOGG1 C326G and XRCC4 G1394T on CRC risk (Table 3). Interestingly, individuals carrying the XPD locus A allele and OGG1 locus G allele showed an increased CRC risk (OR = 1.85, 95%CI = 1.331–2.584, *P* < 0.001; adjusted OR = 1.543, 95%CI = 1.302–2.542, *P* = 0.002). Similarly, the combined effect of the hOGG1 locus G allele and the XRCC4 locus T allele was to increase susceptibility to CRC development (OR = 2.461, 95%CI = 1.826–3.317, *P* < 0.001; adjusted OR = 3.854, 95%CI = 2.293–6.492, *P* < 0.001).
Table 3 Combined effects of XPD751, hOGG1, XRCC4 and CRC risk

| XPD G751A | hOGG1 C326G | XRCC4 G139T | Crude OR (95%CI) | P-value | Adjusted OR (95%CI)* | P-value |
|-----------|-------------|-------------|-----------------|--------|----------------------|--------|
| GG        | CC          | –           | 1               | –      | 1                    | –      |
| GA/AA (A) | CC/GG (G)   | GG          | 1.854 (1.331–2.584) | <0.001 | 1.543 (1.302–2.542) | 0.002  |
| –         | CG/GG (G)   | GT/TT (T)   | 2.461 (1.826–3.317) | <0.001 | 3.854 (1.924–7.123) | <0.001 |
| GG        | –           | GT/TT (T)   | 0.794 (0.572–1.101) | 0.150  | 0.654 (0.787–1.054) | 0.196  |

* 'OR' adjusted by age, sex, alcohol and smoking; CI, confidence interval.

Stratification analysis by smoking for the three gene polymorphisms and CRC risk

We further investigated the associations between the XPD, hOGG1, XRCC4 gene polymorphisms and CRC risk in a study stratified by smoking status. ROC curve analysis was performed to discriminate smoking status. As shown in Figure 2, the area under the ROC curve was 0.72 and the optimal cut-off value was 16 packages/year. The results are shown in Table 4. The risk of CRC in the XPD gene A allele carriers (GA/AA) was significantly higher in patients who smoked ≥16 packs/year (OR = 2.838, 95%CI = 1.490–5.433, P=0.001; adjusted OR = 1.570, 95%CI = 1.201–1.976, P=0.001); the risk of CRC in the hOGG1 gene G allele carriers (CG/GG) increased significantly (OR = 9.938, 95%CI = 5.061–19.694, P<0.001; adjusted OR = 9.938, 95%CI = 5.061–19.694, P<0.001); the risk of CRC in the XRCC4 gene T allele carriers (GT/TT) also increased significantly (OR = 19.695, 95%CI = 7.903–51.271, P<0.001; adjusted OR = 2.793, 95%CI = 2.235–3.222, P<0.001).

Figure 2. ROC curve for smoking status

The area under the ROC curve was 0.72. The optimal cut-off value was 16 packages/year.

1.924–7.123, P<0.001). However, no association between the concurrence of the XPD locus A allele and the XRCC4 locus T allele and the risk of CRC was found (OR = 0.794, 95%CI = 0.572–1.101, P=0.150; adjusted OR = 0.654, 95%CI = 0.787–1.054, P=0.196).
Table 4 Stratification analysis by smoking status for the three gene polymorphisms and CRC risk

| Genes    | Smoking | Genotypes | CRC (n=225) | Control (n=200) | Crude OR (95%CI) | P-value | Adjusted OR (95%CI)* | P-value |
|----------|---------|-----------|-------------|-----------------|-----------------|---------|---------------------|---------|
| XPD G751A | <16     | GG        | 102 (45.33%) | 88 (44.00%)     | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
|          |         | GA/AA     | 12 (5.33%)  | 11 (5.50%)      | 0.941 (0.366–2.427) | 0.891  | 0.972 (0.568–1.640) | 1.000   |
|          | ≥16     | GG        | 62 (27.56%) | 79 (39.50%)     | 1.00 (Ref) | 1.00 (Ref) | 2.383 (1.490–4.033) | 0.001   |
|          |         | GA/AA     | 49 (21.78%) | 22 (11.00%)     | 1.452 (0.660–3.218) | 0.317  | 0.972 (0.813–1.151) | 0.088   |
| hOGG1 C326G | <16    | CC        | 62 (27.56%) | 61 (30.50%)     | 1.00 (Ref) | 1.00 (Ref) | 1.346 (0.751–2.418) | 0.287   |
|          |         | CG/GG     | 52 (23.11%) | 38 (19.00%)     | 1.146 (0.974–1.348) | 0.354  | 1.146 (0.568–2.327) | 0.001   |
|          | ≥16     | CC        | 26 (11.56%) | 76 (38.00%)     | 1.00 (Ref) | 1.00 (Ref) | 9.938 (5.061–19.694) | <0.001  |
|          |         | CG/GG     | 85 (37.78%) | 25 (12.50%)     | 1.176 (0.874–1.576) | <0.001 | 1.176 (0.874–1.576) | <0.001  |
| XRCC1 G139T | <16    | GG        | 92 (40.89%) | 85 (42.50%)     | 1.00 (Ref) | 1.00 (Ref) | 1.452 (0.660–3.218) | 0.317   |
|          |         | GT/TT     | 22 (9.78%)  | 14 (7.00%)      | 1.146 (0.974–1.348) | 0.354  | 1.146 (0.568–2.327) | 0.001   |
|          | ≥16     | GG        | 45 (20.00%) | 74 (38.00%)     | 1.00 (Ref) | 1.00 (Ref) | 19.695 (7.903–51.271) | <0.001  |
|          |         | GT/TT     | 66 (29.33%) | 7 (3.50%)       | 1.146 (0.974–1.348) | 0.354  | 1.146 (0.568–2.327) | <0.001  |

Table 5 Stratification analysis by sexes for the three gene polymorphisms and CRC risk

| Genes    | Sexes | Genotypes | CRC (n=225) | Control (n=200) | Crude OR (95%CI) | P-value | Adjusted OR (95%CI)* | P-value |
|----------|-------|-----------|-------------|-----------------|-----------------|---------|---------------------|---------|
| XPD G751A | male  | GG        | 99 (44.00%) | 95 (47.50%)     | 1.00 (Ref) | 1.00 (Ref) | 0.941 (0.366–2.427) | 0.891   |
|          |       | GA/AA     | 41 (18.22%) | 23 (11.50%)     | 1.00 (Ref) | 1.00 (Ref) | 2.383 (1.490–4.033) | 0.001   |
|          | female| GG        | 65 (28.89%) | 72 (36.00%)     | 1.00 (Ref) | 1.00 (Ref) | 1.346 (0.751–2.418) | 0.287   |
|          |       | GA/AA     | 20 (8.89%)  | 10 (5.00%)      | 1.00 (Ref) | 1.00 (Ref) | 9.938 (5.061–19.694) | <0.001  |
| hOGG1 C326G | male  | CC        | 74 (32.89%) | 95 (47.50%)     | 1.00 (Ref) | 1.00 (Ref) | 1.346 (0.751–2.418) | 0.287   |
|          |       | CG/GG     | 66 (29.33%) | 23 (14.67%)     | 1.00 (Ref) | 1.00 (Ref) | 9.938 (5.061–19.694) | <0.001  |
|          | female| CC        | 14 (6.22%)  | 43 (21.11%)     | 1.00 (Ref) | 1.00 (Ref) | 1.346 (0.751–2.418) | 0.287   |
|          |       | CG/GG     | 71 (31.56%) | 39 (19.50%)     | 1.00 (Ref) | 1.00 (Ref) | 5.592 (2.581–12.269) | <0.001  |
| XRCC1 G139T | male  | GG        | 85 (37.88%) | 102 (18.99%)    | 1.00 (Ref) | 1.00 (Ref) | 2.117 (1.117–3.989) | 0.001   |
|          |       | GT/TT     | 55 (24.44%) | 16 (12.22%)     | 1.00 (Ref) | 1.00 (Ref) | 6.870 (2.862–15.088) | <0.001  |
|          | female| GG        | 52 (23.11%) | 74 (11.56%)     | 1.00 (Ref) | 1.00 (Ref) | 9.938 (7.903–51.271) | <0.001  |
|          |       | GT/TT     | 33 (14.67%) | 7 (3.50%)       | 1.00 (Ref) | 1.00 (Ref) | 1.346 (0.751–2.418) | 0.287   |

Stratification analysis by sexes for the three gene polymorphisms and CRC risk
As there was significant difference in the incidence of CRC between males and females, we studied the impact of sexes on the relationship between the three gene polymorphisms and CRC risk [14]. As shown in Table 5, we observed no association between the XPD, hOGG1, XRCC4 gene polymorphisms and risk of CRC in patients stratified by sexes.

Discussion
CRC is one of the most commonly diagnosed malignancies in East Asia and many other parts of the world. With the development of modern gastrointestinal endoscopy technologies and the establishment of surveillance protocols for individuals at high risk, more cases are diagnosed at the early stages, providing more opportunities for curative treatment.
surgical resection [15]. However, due to the high malignant potential of CRC, approximately 40% of the surgically cured patients experience cancer recurrence within 5 years. CRC usually arises through a multistep carcinogenic process involving the accumulation of numerous genetic and epigenetic changes in oncogenes and suppressor genes, leading to dysregulation of multiple signaling pathways, which disrupt the cell cycle and the balance between cell proliferation and cell death [16,17]. In recent years, considerable interest has arisen in genetic factors that seem to modulate individual susceptibility to multifactorial diseases, characterized by SNPs that can be associated with a predisposition to and a high risk for development of carcinogenesis upon exposure to similar environmental and lifestyle factors [18,19].

Thousands of DNA lesions occur in cells, resulting from exposure to a variety of endogenous and exogenous chemical and physical agents [7]. If not correctly repaired, the accumulation of DNA damage could lead to global genomic instability and DNA rearrangements, which are commonly found in the majority of cancer cells. Efficient repair of this damage helps to maintain DNA stability [8]. There is certain evidence that deficiencies in the DNA repair capacity predispose individuals to an increased susceptibility to cancer [8]. Not surprisingly, individuals with CRC have been reported to have a lower DNA repair capacity. XPD, a prototypical 5'–3' translocating DNA helicase, is part of the transcription factor (TF)IIH complex that is essential for signaling events triggering transcription, cell cycle checkpoints and DNA damage repair [20]. In the present study, we found that the XPD G751A gene polymorphism was associated with an increased risk of CRC, which was consistent with previous studies of other malignancies [21]. The XPD G751A polymorphism caused the amino acid substitution from Lys to Gln, which was closely associated with the impaired DNA repair capacity and thus predisposed individuals to an increased susceptibility to cancer [22,23]. Nevertheless, no significant association was found between the XPD G751A polymorphism and CRC susceptibility in the study from a Polish population [24]. Several reasons may contribute to the inconsistent result. First, Caucasians and Asians have different genetic backgrounds. The minor allele frequency of the XPD G751A genotype in control subjects was significantly lower in Chinese studies than that in Polish studies. Second, cancer is a complex disease affected by interactions between genetic, epigenetic and environmental factors. These factors may modify CRC risk in a distinct way in different populations. In other words, the same genotype of SNP might play an opposite biological role in tumor development in different ethnic groups. It is extremely valuable to address this issue specifically in a Chinese population and it is of great help to determine the relation in larger populations.

Base excision repair (BER) is an important DNA repair pathway of base damage and single-strand breaks caused by X-rays, oxygen radicals or alkylating agents. One of the key enzymes in the BER pathway is human hOGG1 [25]. Genetic variants of hOGG1 may affect the expression and function of the OGG1 protein, thus contributing to the risk of cancer [26], Ser326Cys is the most extensively studied hOGG1 variant, and the Cys326 allele is increasingly reported to be associated with an increased risk of cancer [22,27,28]. Our results indicated that the hOGG1 C326G gene polymorphism and the CRC susceptibility were significantly correlated: the G allele carriers had a higher risk of cancer [26]. Ser326Cys is the most extensively studied variant, and the Cys326 allele is increasingly reported to be associated with an increased risk of cancer [22,27,28]. Our results indicated that the hOGG1 C326G gene polymorphism and the CRC susceptibility were significantly correlated: the G allele carriers had a higher risk of developing CRC, which corresponded well with the previous study by Park et al. [29]. Sliwinski et al. [24] detected the XPD G751A and hOGG1 C326G gene polymorphisms in a Polish population and found no association between the locus gene polymorphisms and the risk of CRC. This discrepancy can be also explained by the different ethnicities studied or the complex underlying genetic architecture or multifactorial genetic factors of CRC as indicated above. But in addition, we noticed that this study contained a very limited sample size, which may as well lead to the controversial finding.

XRCC4, located on chromosome 5q14.2, is an important DNA repair gene involved in the NHEJ pathway. XRCC4 directly interacts with Ku70/Ku80 and plays a central role in the precise end-joining of blunt DSBs [30]. It has been reported that inactivation of the XRCC4 gene causes growth defects, premature senescence, inability to support V(D)J recombination, late embryonic lethality accompanied by defective lymphogenesis, and defective neurogenesis manifested by extensive apoptotic death of newly generated post-mitotic neuronal cells [31]. Mutations in the coding region of this gene might result in a more deficient NHEJ capacity and increase cancer risk. In the present study, we found that the XRCC4 G1394T gene polymorphism had a substantial association with the increasing risk of CRC, in which T allele carriers had a higher risk of CRC (adjusted OR = 4.512, 95%CI = 2.785–7.402, P < 0.001). In consistent with this observation, the T allele homozygotes for this SNP has been demonstrated to exhibit a defective DNA repair capacity and correlate with higher chromosome aberration frequency.

We also examined the joint effects of XPD, hOGG1 and XRCC4 gene polymorphisms on the risk of CRC development and found that the AG/AA genotype of XPD together with the GG genotype of hOGG1 increases the rate of developing CRC. In addition, a combination of the G allele of hOGG1 and the T allele of XRCC4 conferred higher CRC susceptibility. Identifying patients at risk of developing CRC through genotyping may allow a more personalized approach to moderate the risk of CRC development. We further investigated whether tobacco smoking behavior affect the interactions between the polymorphisms and CRC risk. After stratifying the subjects by smoking degree, the
A allele carriers of XPD G751A, the G allele carriers of hOGG1 C326G and the T allele carriers of XRCC4 G1394T were associated with a significantly higher risk of CRC. Tobacco has been recognized as a major risk factor for CRC. It contained a large amount of toxic and harmful substances and can produce free radicals, which can lead to DNA damage [32]. There was great potential that an increase DNA damage and a reduced DNA repair capacity coordinately increase tumor susceptibility. Despite incidence of CRC was higher in males, we observed no association between the three gene polymorphisms and risk of CRC in the stratified analysis based on sexes. This finding was plausible as XPD G751A, hOGG1 C326G and XRCC4 G1394T were common autosomal variants, by which the relationship with CRC risk should not be differed by sexes.

Our findings might be helpful in early detection of CRC through identifying population at risk and the clinical monitoring value is greater among individuals with a severe smoking level. However, these findings should be treated with caution because of the relatively modest sample size and heterogeneity. Well-designed studies with a larger scale and more ethnic groups are needed to validate the risk factor.

**Conclusion**

Our study provided compelling evidence that XPD G751A, hOGG1 C326G and XRCC4 G1394T gene polymorphisms were associated with the susceptibility to developing CRC in a Chinese Han population. Although there were some existing limitations in the study regarding the diversity or ethnicity of samples, our findings provided further insights into the pathogenesis of CRC.

**Author Contribution**

Hongjun Hua conceived the idea, designed research and revised the article. Dexi Jin and Min Zhang collected the samples and performed most of the experiments and statistical analysis. Dexin Jin drafted and revised the article. Dexin Jin performed the study. All authors read and approved the final manuscript.

**Funding**

The authors declare that there are no sources of funding to be acknowledged.

**Competing Interests**

The authors declare that there are no competing interests associated with the manuscript.

**Abbreviations**

BER, base excision repair; CI, confidence interval; CRC, colorectal cancer; hOGG1, human 8-oxoguanine DNA-glycosylase 1; NHEJ, nonhomologous end-joining recombination; ROC, receiver operating characteristic; SNP, single-nucleotide polymorphism; XPD, Xeroderma pigmentosum group D.

**References**

1. Siegel, R.L., Miller, K.D., Fedewa, S.A. et al. (2017) Colorectal cancer statistics, 2017. *CA Cancer J. Clin.* **67**, 177–193, [https://doi.org/10.3322/caac.21395](https://doi.org/10.3322/caac.21395)

2. Chen, W., Zheng, R., Baade, P.D. et al. (2016) Cancer statistics in China, 2015. *CA Cancer J. Clin.* **66**, 115–132, [https://doi.org/10.3322/caac.21338](https://doi.org/10.3322/caac.21338)

3. Brenner, H., Kloor, M. and Pox, C.P. (2014) Colorectal cancer. *Lancet* **383**, 1490–1502, [https://doi.org/10.1016/S0140-6736(13)61649-9](https://doi.org/10.1016/S0140-6736(13)61649-9)

4. Hsu, L., Jeon, J., Brenner, H. et al. (2015) A model to determine colorectal cancer risk using common genetic susceptibility loci. *Gastroenterology* **148**, 1330–1339, [https://doi.org/10.1053/j.gastro.2015.02.010](https://doi.org/10.1053/j.gastro.2015.02.010)

5. Park, J., Kim, I., Jung, K.J. et al. (2015) Gene-gene interaction analysis identifies a new genetic risk factor for colorectal cancer. *J. Biomed. Sci.* **22**, 73, [https://doi.org/10.1186/s12929-015-0180-9](https://doi.org/10.1186/s12929-015-0180-9)

6. Tenesa, A. and Dunlop, M.G. (2009) New insights into the aetiology of colorectal cancer from genome-wide association studies. *Nat. Rev. Genet.* **10**, 353–358, [https://doi.org/10.1038/nrg2574](https://doi.org/10.1038/nrg2574)

7. Ataian, Y. and Krebs, J.E. (2006) Five repair pathways in one context: chromatin modification during DNA repair. *Biochem. Cell. Biol.* **84**, 490–504, [https://doi.org/10.1139/o06-075](https://doi.org/10.1139/o06-075)

8. Nikolaou, A. and Yang, E.S. (2017) The impact of DNA repair pathways in cancer biology and therapy. *Cancers (Basel)* **9**, e126

9. Slyska, J., Cordero, F., Pardini, B. et al. (2015) Post-treatment recovery of suboptimal DNA repair capacity and gene expression levels in colorectal cancer patients. *Mol. Carcinog.* **54**, 769–778, [https://doi.org/10.1002/mc2.22141](https://doi.org/10.1002/mc2.22141)

10. Slyska, J., Naccarati, A., Pardini, B. et al. (2012) Differences in nucleotide excision repair capacity between newly diagnosed colorectal cancer patients and healthy controls. *Mutagenesis* **27**, 225–232, [https://doi.org/10.1093/mutage/ger088](https://doi.org/10.1093/mutage/ger088)

11. Liu, J., Fang, H., Chi, Z. et al. (2015) XPD localizes in mitochondria and protects the mitochondrial genome from oxidative DNA damage. *Nucleic Acids Res.* **43**, 5476–5488, [https://doi.org/10.1093/nar/gkv472](https://doi.org/10.1093/nar/gkv472)
12 Rowland, M.M., Schonhoft, J.D., McKibbin, P.L., et al. (2014) Microscopic mechanism of DNA damage searching by hOGG1. *Nucleic Acids Res.* **42**, 9295–9303, https://doi.org/10.1093/nar/gku621

13 Sharma, M.K., Imamichi, S., Fukuchi, M., et al. (2016) In cellulo phosphorylation of XRCC4 Ser320 by DNA-PK induced by DNA damage. *J. Radiat. Res.* **57**, 115–120, https://doi.org/10.1093/jrr/rrv086

14 Waldmann, E., Heinzle, G., Ferlistich, A., et al. (2016) Risk factors cannot explain the higher prevalence rates of precancerous colorectal lesions in men. *Br. J. Cancer* **115**, 1421–1429, https://doi.org/10.1038/bjc.2016.324

15 Wilke, H.J. and Van Cutsem, E. (2003) Current treatments and future perspectives in colorectal and gastric cancer. *Ann. Oncol.* **14**, i49–i55, https://doi.org/10.1093/annonc/mdg730

16 Armaghany, T., Wilson, J.D., Chu, Q., et al. (2012) Genetic alterations in colorectal cancer. *Gastrointest. Cancer Res.* **5**, 19–27

17 Zoratto, F., Rossi, L., Verrico, M., et al. (2014) Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. *Tumour Biol.* **35**, 6195–6206, https://doi.org/10.1007/s13277-014-1845-9

18 Jia, W.H., Zhang, B., Matsuo, K., et al. (2013) Genome-wide association analyses in East Asians identify new susceptibility loci for colorectal cancer. *Nat. Genet.* **45**, 191–196, https://doi.org/10.1038/ng.2505

19 Jia, Z., Yin, Z., Guan, P., et al. (2009) The association between polymorphisms of XPD and susceptibility of lung cancer: a meta-analysis. *Zhongguo Fei Ai Za Zhi* **12**, 1079–1084

20 Liu, L., Yuan, P., Wu, C., et al. (2011) Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. *Lung Cancer* **73**, 110–115, https://doi.org/10.1016/j.lungcan.2010.11.004

21 Shkarupa, V.M., Mishcheniuk, O.Y., Henyk-Berezovska, S.O., et al. (2016) Polymorphism of DNA repair gene XPD Lys751Gln and chromosome aberrations in lymphocytes of thyroid cancer patients exposed to ionizing radiation due to the Chernobyl accident. *Exp. Oncol.* **38**, 257–260

22 Sliwinski, T., Krupa, R., Wisniewska-Jarosinska, M., et al. (2009) Common polymorphisms in the XPD and hOGG1 genes are not associated with the risk of colorectal cancer in a Polish population. *Tohoku J. Exp. Med.* **218**, 185–191, https://doi.org/10.1620/tjem.218.185

23 Ji, H.X., Chang, W.S., Tsai, C.W., et al. (2015) Contribution of DNA repair xeroderma pigmentosum group D genotype to gastric cancer risk in Taiwan. *Anticancer Res.* **35**, 4975–4981

24 Hung, R.J., Hall, J., Brennan, P., et al. (2005) Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. *Am. J. Epidemiol.* **162**, 945–942, https://doi.org/10.1093/aje/kwi318

25 Park, H.W., Kim, I.J., Kang, H.C., et al. (2007) The hOGG1 Ser326Cys polymorphism is not associated with colorectal cancer risk. *J. Epidemiol.* **17**, 156–160, https://doi.org/10.2188/jea.17.156

26 Murray, J.E., van der Burg, M., Ijspeert, H., et al. (2015) Mutations in the NHEJ component XRCC4 cause primordial dwarfism. *Am. J. Hum. Genet.* **96**, 412–424, https://doi.org/10.1016/j.ajhg.2015.01.013

27 Barnes, D.E., Stamp, G., Rosewell, I., et al. (1998) Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice. *Curr. Biol.* **8**, 1395–1398, https://doi.org/10.1016/S0960-9822(98)00021-9

28 Fan, C.Y. (2001) Genetic alterations in head and neck cancer: interactions among environmental carcinogens, cell cycle control, and host DNA repair. *Curr. Oncol. Rep.* **3**, 66–71, https://doi.org/10.1007/s11912-001-0045-0

© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).